Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FHND1002 for ALS Treatment: Phase 2 | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 2 | 2025-08-22 | NCT07138014 | |
| Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Enrolling by invitation | Phase 1 | 2025-01-20 | NCT06782958 | |
| FHND9041 Versus Afatinib for Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Enrolling by invitation | Phase 3 | 2025-01-06 | NCT06759857 |